Add Yahoo as a preferred source to see more of our stories on Google. September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences ...
Artificial intelligence (AI) is expanding clinical trial access and enabling drug repurposing, according to Vivek Subbiah, MD. He adds that AI supports drug repurposing by uncovering new actionable ...
Eli Lilly and Biogen/Eisai continue to have a hold on the Alzheimer’s disease market after the approvals of their therapies Kisunla (donanemab) and Leqembi (lecanemab) in 2024 and 2023, respectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results